InnoCare Pharma eyes Hong Kong listing

By Jonathan Breen
21 Oct 2019

Chinese firm InnoCare Pharma is looking for permission to list in Hong Kong, having filed a draft IPO prospectus with the city’s stock exchange.

The company has hired Goldman Sachs and Morgan Stanley as the joint sponsors of the listing.

InnoCare is a clinical stage biopharmaceutical company focused on treatments for cancer and autoimmune diseases. It is working on three cancer drug candidates and a handful related to autoimmune diseases, according to ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access:

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: or find out more online here.